[(R)-2-amino-3-((2-(3-nitroazetidin-1-yl)-2-oxoethyl)thio)propanoic acid]

ID: ALA3526571

Chembl Id: CHEMBL3526571

PubChem CID: 118753071

Max Phase: Preclinical

Molecular Formula: C8H13N3O5S

Molecular Weight: 263.27

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  N[C@@H](CSCC(=O)N1CC([N+](=O)[O-])C1)C(=O)O

Standard InChI:  InChI=1S/C8H13N3O5S/c9-6(8(13)14)3-17-4-7(12)10-1-5(2-10)11(15)16/h5-6H,1-4,9H2,(H,13,14)/t6-/m0/s1

Standard InChI Key:  QKZVORRCXYXBOC-LURJTMIESA-N

Alternative Forms

  1. Parent:

    ALA3526571

    ---

Associated Targets(Human)

Whole blood (398 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Whole blood (71 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 263.27Molecular Weight (Monoisotopic): 263.0576AlogP: -1.38#Rotatable Bonds: 6
Polar Surface Area: 126.77Molecular Species: ZWITTERIONHBA: 6HBD: 2
#RO5 Violations: 0HBA (Lipinski): 8HBD (Lipinski): 3#RO5 Violations (Lipinski): 0
CX Acidic pKa: 1.90CX Basic pKa: 9.01CX LogP: -3.85CX LogD: -3.90
Aromatic Rings: 0Heavy Atoms: 17QED Weighted: 0.45Np Likeness Score: -0.60

References

1. Scicinski J, Oronsky B, Taylor M, Luo G, Musick T, Marini J, Adams CM, Fitch WL..  (2012)  Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.,  40  (9): [PMID:22699395] [10.1124/dmd.112.046755]

Source